ICU Medical Inc ICUI
The biggest changes in the 10-K filed Feb 19, 2026, in management's words
10-K, Item 7This fiscal year against the last, and the sentences in the MD&A where management explains each change. Tickdelta picks sentences that name the line, a direction and a cause. It does not write explanations of its own.
Gross margin
Big change, FY to Dec 31, 2025 vs Dec 31, 2024
“Gross margin also increased as a result of price increases, the impact of foreign exchange rates, lower supply chain costs and the realization of integration synergies.”
Read it in the 10-K
Cash from operations
Big change, FY to Dec 31, 2025 vs Dec 31, 2024
The MD&A has no sentence that names a cause for this change.
Revenue
Change, FY to Dec 31, 2025 vs Dec 31, 2024
“Consumables revenue increased in 2025, as compared to 2024, primarily due to new customer installations and increased demand for our Infusion Consumables, Oncology, and Tracheostomy product lines.”
Read it in the 10-K
“Infusion Systems revenue increased in 2025, as compared to 2024, primarily due to increased sales of LVP hardware and dedicated sets.”
Read it in the 10-K
Operating margin
Change, FY to Dec 31, 2025 vs Dec 31, 2024
The MD&A has no sentence that names a cause for this change.
What management said, year by year
The cause given in each 10-K, 2 fiscal years, newest first · MD&A (Item 7)
Each bar is how the line changed that year (from the same 10-K's XBRL). Under it, the sentence in that year's MD&A that names the line, a direction and a cause, word for word. A year with no sentence says so.
Revenue
2 of 2 years explained-
FY 2025 -6.3%
“Consumables revenue increased in 2025, as compared to 2024, primarily due to new customer installations and increased demand for our Infusion Consumables, Oncology, and Tracheostomy product lines.”
Read it in the FY 2025 10-K“Infusion Systems revenue increased in 2025, as compared to 2024, primarily due to increased sales of LVP hardware and dedicated sets.”
Read it in the FY 2025 10-K -
FY 2024 +5.4%
“Consumables revenue increased in 2024, as compared to 2023, primarily due to new customer installations and increased demand for our Infusion Consumables, Vascular Access and Oncology product lines.”
Read it in the FY 2024 10-K“Infusion Systems revenue increased in 2024, as compared to 2023, primarily due to higher sales of our large volume pump ("LVP") dedicated sets on a larger installed base, as well as growth in our ambulatory hardware and dedicated sets.”
Read it in the FY 2024 10-K
Gross margin
2 of 2 years explained-
FY 2025 +2.2 pts
“Gross margin also increased as a result of price increases, the impact of foreign exchange rates, lower supply chain costs and the realization of integration synergies.”
Read it in the FY 2025 10-K -
FY 2024 +1.9 pts
“The increase in gross margin in 2024, as compared to 2023, was primarily driven by lower supply chain costs due to synergies and freight rates, price increases, reduced spend on quality remediation activities and the impact of foreign exchange rate changes which was partially offset by lower manufacturing absorption and higher inventory write-offs.”
Read it in the FY 2024 10-K
Operating margin
0 of 2 years explained-
FY 2025 +0.1 pts
The FY 2025 MD&A has no sentence that names a cause for this change.
-
FY 2024 +0.8 pts
The FY 2024 MD&A has no sentence that names a cause for this change.
Cash from operations
0 of 2 years explained-
FY 2025 -11.9%
The FY 2025 MD&A has no sentence that names a cause for this change.
-
FY 2024 +22.8%
The FY 2024 MD&A has no sentence that names a cause for this change.
Changes are computed from the XBRL figures in the same 10-K. Hover a number to see the line item. Open the 10-K
Sources
The Management's Discussion and Analysis (Item 7) of the latest 10-K, quoted word for word; the changes are computed from the same 10-K's XBRL.
Also
Financials: the numbers year by year.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ICUI/export.csv") into a cell.